Microemulsion as drug delivery system for Peptides and Proteins

Landge Anil, Krishnamoorthy Kannan*
Department of Pharmacy,
Annamalai University, Annamalainagar,Tamilnadu India.
*Corresponding Author: E-mail: egkkanan@yahoo.co.in

Abstract
Microemulsions (MEs) are isotropic mixtures with or without a cosurfactant along with combination of oil, water and surfactant and most stable as per view of thermodynamics. These systems of drug delivery are currently of prior interest to the pharmacists because of their embryonic potential to act as therapeutic enzymes and peptide based drug delivery vehicles with incorporation of a wide range of active therapeutic protein and peptide molecules. These therapeutic macromolecules in microemulsion drug delivery form is not solely based on compositions of the vehicle but also on the internal structure or composition of the phases which may nurture protein drug distribution in the vehicles for enhanced drug solubilisation capacity, ease of preparation, enhancement of bioavailability and maximum shelf life. In order to appreciate the potential of protein based microemulsions as delivery vehicles for enhanced drug permeation via skin and tolerability of these systems, this review offers an overlook on phase behaviour studies formulation of microemulsion with entrapment and various approaches to incorporate proteins and enzymes into microemulsion, protein engineering methods for stable delivery and enhanced bioavailability, various protein drug compatibility study methods including characterization of microemulsions.

Keywords: Dermal, Enzyme, Microemulsion, Peptide, Protein.

INTRODUCTION
Protein and peptide delivery methods have evolved remarkably over the past decades, focusing the major research efforts on the delivery of varieties of essential proteins and peptides with high molecular weight. These macromolecules are distinguished by a poor incorporation into the blood stream when administered orally and also with short half-life, which ascertains the need of a frequent administration in optimum doses to achieve desired therapeutic efficacy. Even more, these biomolecules are very sensitive to physiological conditions (e.g., acidic pH of GI tract) and further may lead to adverse effects after systemic administration in high doses. [1]

Generally, protein drugs expose lipophilic, hydrophilic and also amphiphilic nature, its macromolecular structure and associated substantial physio-chemical hindrance are the basic features strongly interferes with the pharmacokinetic and pharmacodynamic behaviour of the drug in vivo [2]. They also limit the rate of reactions, selected solvent systems and unstable nature in variable environmental conditions which are prime considerable factors in formulation of therapeutic protein-peptide based pharmaceuticals.

Protein and peptide macromolecules are administered systemically by intradermal, subcutaneous, transdermal intravenous, intramuscular and intraperitoneal injections and these formulations often encompass additives (e.g., cosolvents, buffers, preservatives), for improving the stability of the biomolecule in vivo [2, 3]. In this respect, albumin and surfactants including amphiphiles like lecithin exhibits a major role in reducing aggregation and the adsorption processes, thus limiting the probability of protein unfolding, its precipitation and deactivation [4]. High molecular weight, fragile nature and complexity and unreliable structure are the main hurdles in application of protein drugs [5, 6]. Moreover such macromolecules may easily get denatured, degraded and ultimately inactivated during their formulation, storage, and delivery by varieties of physiochemical, and enzymatic processes. Their biopharmaceutical properties also blamed for stability [7].

Bioavailability of protein and poor mucosal permeability is majorly blamed to the varieties of proteolytic enzymes situated in the gut, lungs, and skin [8]. Therapeutic bioavailability is also inadequate due to the rapid clearance from the body due to instantaneous phagocytosis, endocytosis, glomerular filtration, proteolysis due to certain enzymatic processes, and various immunological factors of these active protein molecules [9]. Xeno-proteins like therapeutic antibodies and antisera are antigenic and intrinsically immunogenic. Therapeutic proteins with small molecular weight are generally expelled by the kidneys, whereas larger molecular weight proteins mostly undergo proteolytic degradation. Lipoproteins as well as different glycosylated proteins are targeted majorly by the process called endocytosis and phagocytosis [10] while interleukins, cytokines and hormones are most frequently expelled via systemic circulation by intracellular processing and receptor-mediated endocytosis [11]. Moreover numbers of physiological type of proteins are denatured by proteolysis at particular local sites without reaching appropriate therapeutic levels. Thus far, various studies to enhance the protein bioavailability and focus on altering the physicochemical properties of these therapeutic macromolecules are widely being studies for incorporation of functional additives into innovated drug delivery systems adapted specially for these purpose.

In view of these all facts, colloidal drug delivery systems majorly microemulsions (MEs) targeting intradermal and transdermal sites have become the major focus of this research in improving the therapeutic indices of protein biomolecules (effectiveness and safety) by means of a localized and extended release at the target site, without resulting in undesirable side effects.

Transport of Protein and Peptide Macromolecules Via Skin
Human skin is considered as largest organ of the body. It functions as a barrier against depletion of water and essential compounds from the body, penetration of toxic agents. Moreover it also serves as a medium for absorption of drugs locally and systemically. Due to the structure, physiology and barrier properties of the skin, there are a number of options and complications for drug delivery across the skin. The skin is fabricated of four distinct layers, namely the stratum corneum, the epidermis, the dermis and the subcutaneous tissue. The stratum corneum is about 10 to 15 cell layers thick, is fabrication of corneocytes or dead cells and constitute as the primary barrier to the delivery of most drugs [12]. The intercellular void spaces between such corneocytes are generally filled with sheets of lipid bilayer membranes that are water impermeable; lipid lamellae within the stratum corneum, functions as permeability barrier for
epidermis to water and other penetrants. All intradermal, subcutaneous and transdermal drug delivery requires overcoming this epidermal barrier without interfering the skin functions [13]. A major difference between dermal and transdermal drug delivery, in view of their therapeutic need and efficacy. Dermal delivery is majorly targeted towards various skin disorders such as skin cancer, psoriasis, eczema, acne and other fungal or microbial infections. In the case of dermal delivery, systemic absorption is not important, instead remittance of drugs to the pathological sites, is of major concern [14]. While transdermal type of drug delivery is focused towards achievement of systemic levels of drugs. The drug, passes through the different layers of the skin, and reaches the systemic circulation, to produce its therapeutic effect. Transdermal Drug Delivery (TDD) is advantageous for specific drugs those have a higher first pass metabolism and for those drugs which indicate adverse effects such as ulcerations and colitis conditions in the gastrointestinal tract [15].

Different kinds of mechanisms are involved in penetration of therapeutic protein drugs such as simple transcellular and paracellular diffusion, carrier-mediated transport, active transport and pinocytosis or endocytosis [16]. Protein drugs those having lack of lipophilic nature, contributing for zero passive absorption and is ingested across an epithelial membrane by migration through the intercellular margin between the cells [17]. Normally intercellular space exists between 10 to 50 A˚; therefore such route is not appreciable for large macromolecules. While in case of insulin, it is adsorbed on the microvilli bearing portion of the epithelial cell membrane (apical membrane) and is engulfed by specific types of endocytosis processes [18]. Some of protein and peptides only moves with active transport by binding to the cell surface receptor or binding channels in the epithelial lining of the small intestine (membrane bound vesicles) [19]. However the routine transport mechanism that exist is passive diffusion with reversible way transport: first, paracellular (delivery of drug molecule through the intercellular space between the cells) and another, transcellular (involves migration of drug molecule into or across the cells). Transportation of drugs is majorly blamed for its molecular geometry, lipophilicity and charge of the transport pathway across the mucus membrane [20]. Certain extent of lipophilicity is required in protein biomolecules to get disperse into the epithelial membrane and absorb through transcellular passive diffusion [21]. Oral transport of these biomolecules are contributed by gastrointestinal tract into the systemic circulation is through the muscular mucosa then via the areolar layer or a loose connective tissue layer. Areolar or submucosal are other two intestinal layers join together the mucus and muscular layers [22]. Muscular and mucus layers are most strong layers of the intestine which consists of the loose filamentous connective tissue layer i.e. areolar tissue containing lymph gland, nerves and blood vessels [23]. Though there is success in increased transcellular permeation which earlier disclosed on human Caco-2 monolayer epithelial cell at highest concentration in vitro, even though the binding any ligand on molecules that opens the tight junctions is the essential one which is targeted [24].

**Microemulsion Science**

Microemulsion was first introduced in the 1940s by Hoar and Schulman who formulated a clear, single-phase system by titration of a milky emulsion with hexanol [25]. Since then miniemulsions have been known and abundant studies undertaken in terms of delivery systems, cause of their multiple advantages. Briefly, microemulsions are transparent, optically isotropic and stable systems generally constitution of an oil, water and surfactant(s) [26]. Microemulsions systems are different from emulsions with considering number of factors. Microemulsions are clear transparent and composed of globule size (generally up to 150 nm) [27], while emulsions are milky, coarse dispersions with globule sizes generally in the range of micrometer or slightly below. A large number of small droplets are produced, when microemulsions form. Due to the small size of the droplets in a microemulsion, they possess a large interfacial surface area, from which transport of the drug can occur [28]. Microemulsions generate spontaneously, with or without energy necessity. Most often some energy input (viz. gentle mixing, stirring or heating) enhances microemulsion formation but certain barriers like kinetic energy must be conquered [29].

**Different Theories of Microemulsion Formation**

As far as formulation part concern ME formations is based on three different theories. Those are - mixed or interfacial film theory [30], solubilisation theory [31], and thermodynamic theory [32]. According to thermodynamical theory of stabilization, ME generates spontaneously due to the low interfacial free energy level in consideration with diffusion of particular surfactant in the interfacial layer and also the contribution of major entropy that resolute the mixing of single phase in the other one in the form of abundant small droplets. While in the mixed film theory, the interfacial film is understood in demonstrating dissimilar behaviour towards the aqueous and oily segment of the interface. While the solubilisation theory is considered as swollen micelles, in which oil or water is solubilised the micelle or reverse micelle structures to form single-phase system. However, despite of all the ME theories of formation, the depletions in interfacial tension to a very moderate value is of considered as ultimate importance in the ME formation.

**Pharmaceutical Formulation of Microemulsions**

Pharmaceutically microemulsion systems are designed and formulated by taking into consideration GRAS (generally regarded as safe) and preferably pharmaceutical - grade ingredients, that is, ones earlier used in pharmaceutical formulation and devoid of serious adverse effects and toxicity in humans [33]. Nonionic and zwitterionic surfactants are among the most commonly used ingredients to formulate pharmaceutical MEs while vegetable oils, medium - and long - chain triglycerides, and fatty acids ester are the most generally used oils [34].

It is a general concept that, low HLB (about 3-6) surfactants are most preferential for the formulation of w/o microemulsion, while surfactants with higher value of HLB (about 8-18) are recommended for the o/w type microemulsion formulation. Surfactants with HLB value greater than 20 are mostly used along with the co-surfactants to minimise their overall effective HLB value within the accepted range for microemulsion formation [35]. This can be regarded as thumb rule while selecting oil phase, surfactants and cosurfactants with prime concern of stability of ME.

**Aqueous Phase**

An essence of the aqueous phase is a paramount factor for formulation of peptide based microemulsions. In consideration of parenteral microemulsions, the aqueous phase must be isotonic and isosmotic to the blood which can be attained by using additives such as electrolytes (sodium chloride), sorbitol, dextrose, and glycerol. These additives can resolve the microemulsion area of existence [36]. Phase inversion temperature (PIT) of the non-ionic type surfactants can be minimised by electrolytes like sodium chloride [37].

**Oil Phase**

Oil phase also having its most requisite role in the formulation not only because one can solubilise the required dose of the lipophilic drug, but it boosts the lipophilic drug transportation via the lymphatic system in intestine and thereby enhancing absorption in the gastrointestinal tract based on the molecular nature of particular triglyceride [38].
Table 1: List of surfactants commonly used in protein and peptide based microemulsion.

<table>
<thead>
<tr>
<th>Class</th>
<th>HLB status</th>
<th>Examples</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cationic surfactants</td>
<td>--</td>
<td>Cetyltrimethylammonium bromide, Cetylpyridinium chloride and other salts</td>
<td>[42]</td>
</tr>
<tr>
<td>Anionic surfactants</td>
<td>--</td>
<td>Deoxycholate, and its salts, ursoodeoxycholic acid, and taurocholic acid; C_{14} to C_{20} monoesters of lactic acid; C_{10}-C_{18} sulfonates, including alkyl-, olefin- and alkylaryl derivatives; C_{10} to C_{18} diesters of tartaric acid, tridecyl- and dodecylbenzene sulfonic acids; and C_{9} to C_{12} sarcosine and betaine derivatives. Phospholipids such as phosphatic acid and phosphatidyl serine.</td>
<td>[43]</td>
</tr>
<tr>
<td>Zwitterions</td>
<td>--</td>
<td>phospholipids as lecithin, phosphatidyethanolamine, and sphingomyelins</td>
<td>[44]</td>
</tr>
<tr>
<td>Non-ionic surfactants</td>
<td>Low HLB</td>
<td>C_{10} to C_{18} monoglycerides (HLB 4-7), C_{10} to C_{22} diglycerides of mono and poly unsaturated fatty acids (HLB 3-5), C_{23}-C_{32} diglycerides (HLB 4-6), and C_{12} to C_{17} diglycerides of mono and poly unsaturated fatty acids (HLB 2.5-4.5);</td>
<td>[45]</td>
</tr>
<tr>
<td></td>
<td>High HLB</td>
<td>C_{12-14} ethoxylated fatty esters; C_{14-16} sucrose fatty esters; and C_{16-18} sorbitol and sorbitan monoesters, diesters, and triesters, polyoxyethylene sorbitan monooxlate, sorbitol hexaoxlate POE (50). Ethoxylated castor oil (HLB 10-16); and the sorbitan surfactants with HLB from 10-18.</td>
<td></td>
</tr>
</tbody>
</table>

The oil component alters curvature by its capability for penetration and expansion of the tail region of the monolayer of surfactant. Short chain oils perforate the tail group region to a larger extent than long chain alkanes, and hence expand this region to a larger extent, developing in increased negative curvature (and hence reduced effective HLB). Saturated (for example, lauric, myristic and capric acid) and unsaturated fatty acids (for example, oleic acid, linoleic acid and linolenic acid) have penetration enhancing property of their own and those have been studied since a long time. Fatty acid esters such as ethyl or methyl esters of lauric, myristic and oleic acid have also been employed as the oil phase [39]. Lipophilic drugs are most precisely solubilised in oil/water microemulsions. The intensity while choosing the oil phase is that the drug should be highly solubilised in it, which minimises the volume of the formulation to deliver the required dose of the therapeutic drug in an encapsulated form [40].

**Surfactants:**

The selection of suitable surfactant system is one of the most crucial step in the designing a ME system. In ME, oil system solubilisation carries most important factor than other micellar solutions. It is feasible for one surfactant molecule, to solubilise 10 to 20 oil molecules (o/w ME) or 10 to 200 water molecules (w/o ME). The surfactant(s) need to dissolve and lower the interfacial free energy to very low level (<10−10 to 20 oil molecules (o/w ME) or 10 to 200 water molecules (w/o ME)). The surfactant(s) to dissolves and lower the interfacial free energy to very low level (<10−10 to 20 oil molecules (o/w ME) or 10 to 200 water molecules (w/o ME)).

Generally all anionics surfactants such as S.L.S. are extremely soluble in water & very little soluble in oil/fats and even almost all cationics and amphotetics shows higher solubility in water, while nonionics’ water solubility can be predicted by their HLB values. Various ionic and non-ionic types of surfactants in consideration of protein based microemulsion system are reviewed here in table 1.

**Cosurfactants/ cosolvents**

Cosurfactants are molecules with weak amphiphilic properties that are mixed with the surfactant(s) to enhance their ability to reduce the interfacial tension of a system and promote the formation of a ME [46]. Most single - chain surfactants do not sufficiently lower the oil – water interfacial tension to form MEs, nor are they of the right molecular structure to act as cosolvents. Such barrier can be conquered as cosurfactant /cosolvent molecules are considered to minimise the interfacial free energy in between oil and water, hydrocarbon boundary of the interfacial film can be fluidised which ultimately determine impact the curvature of the film [44]. Choice of cosurfactants for therapeutic protein candidates are alcohols preferred from the group comprising of ethanol, isopropanol, n-butanol, Lecithin etc. and isobutanol, propylene glycol, polyethylene glycol and isopropyl myristate [47].

**Buffers/ Stabilisers**

Protein stabilization is improved by certain buffers like acetate, citrate, histidine, glycine, methionine, tartarate, lactate, succinate either alone or in combination thereof are also included [44].

**Phase Behaviour Studies**

In order to understand the phase behaviour of any microemulsion, pseudo-ternary phase diagrams of water, oil and co-surfactant/surfactants mixtures at particular point of ternary system or phase triangle is drawn with appropriate cosurfactant or surfactant weight ratios. Phase diagrams are obtained by mixing of the ingredients, which earlier pre-weighed into glass vials and titrated with water and stirred well at room temperature. A typical pseudo-ternary phase diagram is indicated for formulation of various colloids systems with consideration of different phases in figure 1. Development of either monophasic or biphasic system is identified by visual inspection. If there is formation of turbidity followed with a phase separation, the systems are called biphasic while in earlier case monophasic which indicates fine, clear-cut and transparent mixtures that can be visualized after homogenisation; these samples are identified at particular points in the ternary phase diagram. The area covered by these different points is regarded as the microemulsion boundary region of existence. [48]

Figure 1: Pseudo-ternary phase diagram representing the different regions of various types of colloids.
According to biodistribution studies, the molecule rapidly monoclonal antibodies Remicade™ and Humira™, in water-in-oil administration of the high molecular weight proteins, anti-TNF studies using animal models demonstrated that the topical delivery of peptides effectively into the dermal layer [57, 58]. Different entrap protein/peptides in the aqueous droplets and deliver the microemulsions were used as they are particularly suitable to emulsions for dermal peptide delivery in human skin. Water-in-oil vehicle structure allows faster transport of hydrophilic drugs [57]. The microemulsion formulation meant for dermal or transdermal biology with wider pertinent merely than biocatalyst action [56]. Enzyme therapeutics in w/o type microemulsions are in sense to influence these bilayer types of structures upon inclusion into both monolayers. It is also noticed that many enzymes and proteins micelles units as in sandwich form between polar lipid interfacial contact in between the enzyme molecule and the organic solvent system that attributes to the enzyme deactivation.

Several variables are having their own role during the solubilisation of proteins in microemulsions, including the pH and the ionic strength of the aqueous phase, the molecular and structural size of the protein, the size of the reverse micelles, and the nature of the surfactant [57, 58]. The nature of the micellar interface, while a typical protein uptake into the aqueous microphase is a complicated process. It was proposed that the lipophilicity of the protein molecule plays major role in its localization among the various microenvironments of the system. In fact, a lipophobic protein can avoid direct contact with the continuous organic phase and remain localized in the water layer; certain surface active enzyme (such as some lipases) produces an interfacial interaction with the micellar interface, while a typical membrane protein could be in conjunction with the hydrophobic boundary line of the micelles and also with the organic solvent [54, 55].

In biological system many proteins and enzymes wield at interface of hydrophilic and hydrophobic domains and these interfaces are usually under stabilisation of polar lipids and certain natural amphiphiles. Lipid particles also can be viewed as reverse micelles units as in sandwich form between polar lipid monolayers. It is also noticed that many enzymes and proteins influence these bilayer types of structures upon inclusion into both model and biological membranes. Hence delivery of proteins and enzyme therapeutics in w/o type microemulsions are in sense to biology with wider pertinent merely than biocatalyst action [56].

The microemulsion formulation meant for dermal or transdermal type is of relevance for skin absorption. The water in continuous vehicle structure allows faster transport of hydrophilic drugs [57]. There are a wide range of reported studies using microemulsions for dermal peptide delivery in human skin. Water-in-oil microemulsions were used as they are particularly suitable to entrap protein/peptides in the aqueous droplets and deliver the peptides effectively into the dermal layer [57, 58]. Different studies using animal models demonstrated that the topical administration of the high molecular weight proteins, anti-TNF monoclonal antibodies Remicade™ and Humira™, in water-in-oil microemulsions reduced inflammation in the feet of mice [59]. According to bio distribution studies, the molecule rapidly penetrated into the skin and also perforated laterally into the distal regions of the skin with approximately 70% of the protein found in the skin. In one research article in vivo studies on mice reported on reduction in inflammatory footpad condition of carrageenan induced mice followed with the topical administration of anti-TNF molecules that was formulated via microemulsion system [60].

It is well known that protein based biological are not appropriate dosage forms for oral route administration due to macro size, polarity and unequal charge distribution on protein therapeutics also it may undergo enzymatic breakdown through proteolysis in the gastrointestinal tract and ultimately poor therapeutic index. Most biologicals are available as aqueous injectable components that require repeated dose regimen and frequent visits to the health service providers. The development of a self administrable delivery system would enable patients to avoid discomfort and enhancing patient compliance [61].

Different Approaches To Incorporate Proteins, Peptides and Enzymes In Microemulsion
(a) Self-Emulsifying Drug Delivery Systems (SEDDS)
Self-emulsifying drug delivery systems (SEDDS) are one of most novel and comprehensive approach for incorporating of protein in microemulsion. It is under extensive research after the market success of HIV protease inhibitors, ritonavir (Norvir) and saquinavir (Fortovase), and cyclosporin (Neorals or Sandimmunes) formulations. SEDDS do possess lipidic excipients to improve solubility and permeability of drug substances. These lipid based excipients get emulsified when exposed to gastrointestinal fluids to form oil-in-water emulsions or microemulsions [62, 63]. By considering the globule size, SEDDS can be classified either as self-microemulsifying drug delivery systems (SMEDDS) and another one as self-nano-emulsifying drug delivery systems (SNEDDS). SNEDDS are clear and transparent microemulsions with globule size range between 100 to 250 nm, while the globule size of SNEDDS is less than 100 nm [64].

(b) Self-Nano-Emulsifying Drug Delivery Systems (SNEDDS)
Self-Nanoemulsifying Drug Delivery System (SNEDDS) has majorly developed for protein drug delivery via oral route as it devoid of water, hence long term preserving the stability of protein, protecting protein from proteolytic degradation, and augmenting the permeability of therapeutic protein-drug in the gastrointestinal tract. However, due to low solubility of protein in oil, which is almost towards zero, protein-based SNEDDS formulations are difficult and challenging. SNEDDS system was found most compatible for proteins using HLβ approach by Lina Winarti et. al. in 2016 [65]. It is investigated that SNEDDS with single hydrophilic surfactant is one of the best content in formula for stability testing of protein template as recipe showed that precipitation or phase separation did not appear by employing model protein such as bovine serum albumin (BSA) during study [65].

(c) Solid-Lipid Nanoparticles (SLN’S)

Oral absorption of drugs can be enhanced by lipids [66]. An excellent model drug such as Cyclosporin A in the form of microemulsion reduces the bioavailability variation of protein molecule. In the early 1960s, the first parenteral administration (Intralipid) began the administration of lipophilic drugs. In the early 1990s, various groups focused attention on solid lipid nanoparticles. As the name implies, these nanocarriers contain solid lipids. They have the advantages of physical stability, controlled release, and low toxicity; they also help in protecting sensitive drugs from degradation from the external environment. They are generally prepared with physiological lipids or molecules that have a history of safe use and are better tolerated than the polymeric carriers. Additionally, organic solvents are not
being utilised which makes them better candidates compared to many of the polymeric systems.

There are three important variations of lipid nanoparticles tested in the pharmaceutical literature: solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and lipid drug conjugates (LDCs). Varieties of research works have also constantly targeted on improving stability of SLN’s in body fluids with hydrophilic coating molecules viz. poly(ethylene)glycol (PEG) derivatives. Hydrophilic molecule’s coating to SLN not only enhances plasma stability but also biodistribution resulting subsequent bioavailability of entrapped drugs [67].

(d) Convertible/ Phase Reversible Microemulsion

Stable w/o microemulsions are formed when HLB value of the microemulsion is between 9 and 12. It is achieved by using high HLB value surfactants are used in combination with low HLB surfactants in the patent invention by Albert J. Owen et. al [44].

Any water soluble biologically active entity in the aqueous phase is liberated for body absorption reason as water in oil (w/o) microemulsion which freely converts phase to an oil in water (o/w) emulsion by the incorporation of aqueous fluid to the said w/o microemulsion. Short chain monoglyceride surfactant that is widely employed as storage depot for proteins and remain stable for longer duration at room temperature and above until they are ready for use in w/o microemulsion.

While at particular period of time the addition of aqueous fluid samples which converts the microemulsion into an o/w emulsion and subsequently releases the therapeutic protein. The precisely stored w/o type convertible microemulsion can be delivered to the body where it is does convert into an o/w emulsion by the interacting with different body fluids. Advantage of such delivery system is by this manner, peptide microemulsion storage problems also minimised. [44].

Table 2: Different phases used in w/o type microemulsions as vehicles for protein and peptide drug delivery in various disorders

<table>
<thead>
<tr>
<th>Sr.</th>
<th>Protein/Peptide</th>
<th>Aqueous phase</th>
<th>Oil Phase</th>
<th>Surfactants</th>
<th>Cosurfactants</th>
<th>Advantages</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>HIV transactivator protein TAT (TAMRA-TAT)</td>
<td>Water</td>
<td>Miglyol 812</td>
<td>Capmul MCM</td>
<td>Tween 80</td>
<td>Antiviral</td>
<td>[69]</td>
</tr>
<tr>
<td>2</td>
<td>Insulin</td>
<td>Water</td>
<td>Isopropyl myristate or oleic acid</td>
<td>Tween 80</td>
<td>Isopropanol</td>
<td>Diabetes Type-I</td>
<td>[70]</td>
</tr>
<tr>
<td>3</td>
<td>P42 Peptide</td>
<td>Water</td>
<td>The lipid mixture</td>
<td>TAMR</td>
<td>---</td>
<td>Huntington Disease</td>
<td>[71]</td>
</tr>
<tr>
<td>4</td>
<td>Ovalbumin (Ova) and Quil A</td>
<td>water, ethanol</td>
<td>Isopropyl myristate</td>
<td>Capryl-caprylyl glycoside (CCG)</td>
<td>Lechitin</td>
<td>Model antigenic vaccine</td>
<td>[72]</td>
</tr>
<tr>
<td>5</td>
<td>Lidocaine</td>
<td>water, ethanol</td>
<td>Olive oil</td>
<td>Miglyol1</td>
<td>Lechitin</td>
<td>Local anaesthetic</td>
<td>[73]</td>
</tr>
<tr>
<td>7</td>
<td>Bletaongue virus serotype 4 inactivated suspension</td>
<td>Inactivated virus suspension</td>
<td>Isopropyl myristate</td>
<td>α-hydroxy-ω-hydroxypropyl- oxyethylene-poly(oxypolypropylene)</td>
<td>Polysorbate 80</td>
<td>Antiviral</td>
<td>[74]</td>
</tr>
<tr>
<td>8</td>
<td>Aprotinin</td>
<td>0.9% NaCl</td>
<td>Isopropyl myristate and oleic acid</td>
<td>Labrasol and CR</td>
<td>Ethanol and Isopropanol</td>
<td>In pancreatitis therapy as a protease inhibitor,</td>
<td>[75]</td>
</tr>
<tr>
<td>9</td>
<td>Insulin</td>
<td>Phospholipid dispersion with buffers</td>
<td>Glyceryl monooleate (GMO), Tween 20, and polyethylene glycol (PEG 400)</td>
<td>Tween 20</td>
<td>---</td>
<td>In Hyperglycemia</td>
<td>[76]</td>
</tr>
</tbody>
</table>
Liberate the active parent drug entity which has to undergo known as biological inert compound derivatives of a drug entity to minimize unwanted toxicity and to increase optimize the pharmacokinetics (ADMET properties) and pharmacodynamic objective is to reduce irritation and pain upon local administration. 2. Pharmacokinetic objective is to enhance absorption to diminish presystemic metabolism and same time to enhance time profile for increased metabolism and/or chemical conversion in vivo. The active drug component would be liberated from its native inactive form, during or after absorption of the prodrug. Certain prodrugs are released into their active form after reaching at particular target site for their pharmacological actions \[79, 80\]. In accordance to Testa \[81\], there are primarily three basic intentions in prodrug research: 1. Pharmaceutical objective is to enhance solubility, stability, and organoleptic properties and same time to lessen irritation and pain upon local administration. 2. Pharmacokinetic objective is to enhance absorption to diminish presystemic metabolism and same time to enhance time profile for increased organ/ tissue-specific transportation of the active therapeutic macromolecule. 3. Pharmacodynamic objective is to reduce toxicity and to improve therapeutic index, to design single drug entities combining two active moieties (co-drugs strategy).

**Penetration Enhancers**

Though some proteins and peptides themselves can act as penetration enhancers to enhance dermal delivery of other proteins, various chemical used for penetration through skin are also called as sorption promoters or accelerants) have been used for the augmentation of skin penetration since long \[82\]. The mechanism of action is complex specific with most interacting with the lipid domain of the stratum corneum, disrupting these, and causing fluidization. Other mechanisms include breaking of the motif packing, domains present, metabolic processes or altering thermodynamic activity \[82\]. When coadministered with a peptide/protein their action on the skin is to improve the protein penetration. For supporting this statement, Magnusson and Runn \[83\] reported a remarkable increase in the flux of thyrotropic releasing hormone, with the use of ethanol and cineole across human epidermis in vitro. While there have been a number of successful permeation enhancers employed for peptide delivery to the skin, their use is hampered at high concentrations by irritation \[84\]. Examples of such chemical enhancing agents include the use of dimethylsulphoxide, azote pyrrolidones and fatty acids or fatty alcohols amongst others.

### Table 3: Different methods for preparation of various forms of microemulsion

<table>
<thead>
<tr>
<th>Technique</th>
<th>Process</th>
<th>Approach Type</th>
<th>Type</th>
<th>Protein Incorporation method</th>
<th>Example</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase Titration for W/O and O/W</td>
<td>Homogenisation</td>
<td>General Approach</td>
<td>W/O</td>
<td>Solubility by HLB and phase titration</td>
<td>Aprotinin</td>
<td>[89]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>O/W</td>
<td>Ultra High Pressure Homogenisation</td>
<td>Whey Protein</td>
<td>[90]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nanoparticle Approach</td>
<td>SLN</td>
<td>Adsorption onto SLN</td>
<td>BSA, IHA</td>
<td>[91, 92]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Solvent evaporation (w/o/w)</td>
<td>Interferon-alpha (IFN-alpha)</td>
<td>[93]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HPH hot dispersion</td>
<td>Cyclosporin</td>
<td>[94]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HPH cold dispersion</td>
<td>Cyclosporin</td>
<td>[95]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Warm microemulsion (o/w)</td>
<td>Cyclosporin</td>
<td>[96]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Solvent displacement</td>
<td>Gonadorelin</td>
<td>[97]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Encapsulation</td>
<td>HIV-1 gp120 antigen</td>
<td>[98]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Processing using Supercritical CO2</td>
<td>SEDDS</td>
<td>Solid carriers</td>
<td>Monoclonal Antibodies</td>
<td>[99]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Spray Drying</td>
<td>Insulin</td>
<td>[100]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Melt Extrusion</td>
<td>Insulin</td>
<td>[101]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dry Emulsion</td>
<td>Milk Proteins</td>
<td>[102]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SNEDDS</td>
<td>Solubility by HLB and phase titration</td>
<td>Bovine Serum Albumin</td>
<td>[65]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SEDDS</td>
<td>Solubility by HLB and phase titration</td>
<td>Bovine Serum Albumin</td>
<td>[103, 104, 105]</td>
</tr>
<tr>
<td>Phase Inversion /Bicontinuous</td>
<td>Autoemulsification</td>
<td>Convertible type</td>
<td>O/W to W/O</td>
<td>Solubility by HLB and phase titration</td>
<td>Growth Hormone Releasing Peptide</td>
<td>[45]</td>
</tr>
<tr>
<td></td>
<td>Factors viz. temperature, viscosity, Refractive Index etc.</td>
<td>SEDDS</td>
<td>and vice versa</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(e) **Microemulsions with Adsorbed Macromolecules and Microparticles**

Various types of biocompatible and biodegradable polymers, like polycaprolactone, polylactoester, polyanhydride including poly(o-hydroxy acid), polyhydroxy butyric acid, poly(lactide-co-glycolides) i.e. PLG and so on along with routine synthetic polymer polyethylene glycol (PEG), are synthesised using different ionic surfactants. Biologically active macromolecules such as nucleic acids, different polypeptides, antigenic proteins, and adjuvant, along with compositions of metabolisable oil and an emulsifying agent are efficiently adsorbed by the surface area of such microparticle polymers. Most immunogenic components composed of an antigenic substance which provokes immunogenic response. Wide studies by researchers resulted into methods of generating microparticles with presence of adsorbent surfaces with use of tetraethylorthosilicate (TEOS) for variety of macromolecules. These invented microparticles shall get adsorbed over such macromolecules in more coherent and efficient manner than any other microparticles available currently \[68\].

These various approaches of incorporation of proteins and peptides are summarised with diagrammatic representation as below in figure 2.

Various newly innovated or in pipeline staged water in oil (w/o) type of protein /peptide microemulsion vehicles for delivery in different disorders are discussed in table 2.

**Protein Engineering Approaches for Stable Delivery of Protein Therapeutics with Enhanced Bioavailability.**

(a) **Prodrug strategy**

The rationale behind use of prodrugs approach is to optimize the pharmacokinetics (ADMET properties) and pharmacodynamic (to minimise unwanted toxicity and to increase therapeutic index) limitations of the parent drugs \[77\]. Prodrug concept was invented first in 1958 by Adrien Albert \[78\], which is known as biological inert compound derivatives of a drug entity to liberate the active parent drug entity which has to undergo metabolic and/or chemical conversion in vivo. The active drug component would be liberated from its native inactive form, during or after absorption of the prodrug. Certain prodrugs are released into their active form after reaching at particular target site for their pharmacological actions \[79, 80\]. In accordance to Testa \[81\], there are primarily three basic intentions in prodrug research: 1. Pharmaceutical objective is to enhance solubility, stability, and organoleptic properties and same time to lessen irritation and pain upon local administration. 2. Pharmacokinetic objective is to enhance absorption to diminish presystemic metabolism and same time to enhance time profile for increased organ/ tissue-specific transportation of the active therapeutic macromolecule. 3. Pharmacodynamic objective is to reduce toxicity and to improve therapeutic index, to design single drug entities combining two active moieties (co-drugs strategy).
and/or substances to promote preferential hydration of the protein. Mechanistic paradigms may involve one or more of the following: (i) examination of the denatured state of the protein in the polymer; (ii) characterization of the deleterious stress(es) responsible for the instability mechanism; (iii) simulating the instability of the protein in the polymer matrix; (iv) use of a model protein to isolate one deleterious stress or mechanism of interest; (v) use of a simpler polymer matrix; (vi) use of anhydrous protein encapsulation (to eliminate significant protein instability during encapsulation); (vii) use of combinations of points (i) to (vi) to elucidate the deleterious cause and mechanism of protein instability; and (viii) use of the elucidated instability pathway to develop rational approaches to protein stabilization. Adding adsorption competitors (e.g., albumin) and/or substances to promote preferential hydration of the protein (e.g., trehalose) are two approaches shown useful to minimize instability during preparation by the w/o/w emulsion-solvent evaporation method [85].

**PEGylation**

One of the most extensively studied approaches for administration of various proteins and peptides via parenteral routes is PEGylation which involves covalent conjugation of activated polyethylene glycol (PEG) to the therapeutic proteins or peptides of interest. PEGylation is beneficial not only in enhancing stability of protein drugs but pharmacokinetics, and therapeutic activity of therapeutic peptide drugs could be enhanced by altering molecular mass, size, shape, solubility criteria and steric hindrance of native protein drugs [10]. Minimal cellular adsorption among all known polymers used for drug delivery, nontoxic properties, nonimmunogenicity, water solubility and FDA approval for injection with biotechnology based recombinant drug products are basic unique characteristics of PEG which make them choice of polymers for parenteral route administration of therapeutic proteins and enzymes [86].

PEGylation process inhibits serum-opsonin reaction with therapeutic peptide drugs and enzymes, hence minimal clearance at cellular level by the reticuloendothelial system. PEGylation is also known in inhibition of protein degradation caused by receptors interaction and proteolytic enzymes and even specific certain cell-protein interactions. Because of such classical features, clearance of therapeutic proteins and peptides is significantly lowered before its onset of action at site and ultimately frequency of administration can be reduced with optimal therapeutic efficacy [86]. In one study, PEGylation has been caused to enhance in vivo performance of recombinant human growth hormone (hGH) [87]. Similarly, it also proved advantageous in enhancing half-life of recombinant human thyroid stimulating hormone [88].

**Glycosylation**

Glycosylation has been one of the highly studied subjects for protein and peptide delivery. It is process involving conjugation of proteins, lipids and varities of organic molecules with polysaccharides to generate “glycoconjugate”. The nature of the carbohydrate conjugated to the protein determines and regulates its structure, function, activity, immunogenicity and pharmacokinetic profile. Various attempts have been carried out on hyperglycosylation of therapeutic proteins drugs to enhance its pharmacokinetic properties. Pharmacokinetics of enzymes such as catalase and asparaginase are improved by colominic acid by glycosylation process. It is also showed that hyperglycosylation of recombinant Factor IX, a blood coagulation factor used to treat Hemophilia B, improved and prolonged its systemic circulation duration relative to its native protein [89].

**Mannosylation**

Mannosylation is a process of mannose moiety conjugation with protein receptor. Macrophages Kupffer cells, monocyte-derived dendritic, cells alveolar and different subsets of lymphatic and vascular endothelial cells are representative of mannose receptors. Different mannosylated proteins (Man17-superoxide dismutase [SOD], Man21-SOD, Man12- bovine serum albumin [BSA], Man16-BSA, Man25-BSA, Man35-BSA, Man46- BSA and Man32-IgG and Man42-IgG showed success in mannmosylation of which proteins were taken up mainly by liver and uptake saturated with increasing doses [90].

**Enzyme Inhibitors**

In addition to direct protein modification methods, one is to co-administer with enzyme inhibitors to increase peptide bioavailability. These enzyme inhibitors are usually more effective in the oral and intestinal delivery of protein therapeutics due to variety of proteases present over there. A well-known enzyme inhibitor is soybean trypsin inhibitor, a potent and specific inhibitor of chymotrypsin. Trasylol™, an original brand of aprotinin used to control bleeding during complicated surgeries, is an enzyme inhibitor used in combination with insulin [89].

Various formulation strategies by employing these approaches and different processes are discussed briefly in table 3.

**Drug–Excipient Compatibility Studies for Protein/Peptide Drugs**

During pre-formulation studies varieties of thermal and non-thermal analytical techniques are employed for earlier prediction of suitable excipients for specific dosage forms for minimising untoward incompatibility reactions and stability issues which may arise in final formulation [107]. There is no any specific or universally accepted procedure is available for prior evaluation the compatibility of protein drug with other excipients till date. However, few reports have published in the last decade that accentuate the use of various analytical tools used in the compatibility screening of therapeutic active drug candidate in search of suitable additives or excipients. The most routinely used techniques for drug compatibility screening studies include thermal methods such as differential thermal analysis, differential scanning calorimetry, thermo gravimetric analysis, isothermal micro calormetry and hot stage microscopy.

**Table 4: Different analytical tools for compatibility assessment of protein-excipients compatibility studies.**

<table>
<thead>
<tr>
<th>Technique Used</th>
<th>Analytical method</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Spectral Techniques</strong></td>
<td>X-ray diffraction (XRD)</td>
<td>[109]</td>
</tr>
<tr>
<td></td>
<td>UV-Vis Spectroscopy</td>
<td>[110]</td>
</tr>
<tr>
<td></td>
<td>Nuclear magnetic resonance spectroscopy (NMR)</td>
<td>[111]</td>
</tr>
<tr>
<td></td>
<td>Circular Dichroism</td>
<td>[112]</td>
</tr>
<tr>
<td><strong>Microscopic Technique</strong></td>
<td>Scanning electron microscopy (SEM)</td>
<td>[113]</td>
</tr>
<tr>
<td><strong>Chromatographic Technique</strong></td>
<td>High performance liquid chromatography</td>
<td>[114]</td>
</tr>
<tr>
<td></td>
<td>Mass Spectroscopy</td>
<td>[115]</td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td>Peptide Map</td>
<td>[116]</td>
</tr>
<tr>
<td></td>
<td>SDS-PAGE</td>
<td>[117]</td>
</tr>
<tr>
<td></td>
<td>Western Blot</td>
<td>[118]</td>
</tr>
<tr>
<td></td>
<td>Iso-Electric Focusing</td>
<td>[119]</td>
</tr>
<tr>
<td></td>
<td>Protein Assays</td>
<td>[120]</td>
</tr>
<tr>
<td><strong>In-Silico Prediction</strong></td>
<td>Predictive software</td>
<td>[121]</td>
</tr>
</tbody>
</table>
Since these techniques are being utilised widely now days, hence are avoided here for discussion. These techniques differ in their working principles, mechanical stress that is applied to the sample, time of analysis and amount of sample required, sensitivity of the technique to minute changes, and the necessity of internal or external standards [108]. Certain reported techniques for the evaluation of drug-excipient compatibility generated lower predictive value while others are time consuming processes in the pharmaceutical product development. Therefore utilisation of thermal and non-thermal methods is advocated during determination of incompatibility.

Techniques Used To Characterize Microemulsion

In the pharmaceutical field, MEs are the group related to colloidal drug delivery systems and can therefore be processed for several physicochemical and analytical techniques in order to characterize conventional colloids. There are varieties of techniques used in the characterization of ME and related systems along with relevant examples will be described below. General physical appearance microemulsion can be inspected visually for homogeneity, fluidity and optical clarity.

(a) Globule Size and Zeta Potential Measurements

Microemulsion can be characterised for the globule size and zeta potential by techniques called dynamic light scattering, using a Zetasizer. The measurement of average globule size in microemulsion at nano scale level can be determined to characterise either the said emulsion is micro or nanoemulsion [124].

(b) Conductivity & pH

Drug loaded microemulsions can be checked for electrical conductivity (σ) using a (Elico CM 180) conductivity meter. This help us to ascertain if the system is oil-continuous, bi-continuous or water continuous, moreover pH of microemulsions can be recorded at 25±1°C using (Mettler Toledo, pH compact 220) pH meter. [122].

(c) Viscosity

Viscosity measurement of the microemulsions may be done in triplicates using Brookfield viscometer [123].

(d) Drug Solubility

Drug solubility is assessed by continuous stirring the formulation under observation for 24 h at room temperature, further samples shall be withdrawn and centrifuged at about 6000 rpm for 10 min. The quantitative estimation of soluble drug in the optimized formulation and also in each individual formulation can be retrieved by difference between the drugs present in the sediment and the total amount of drug added. Dissolved drug’s solubility in microemulsion can be compared with that of individual ingredients [123].

(e) Lipidity Test (Percent Transmittance Test)

The limpidity test on microemulsions can be carried out spectrophotometrically using UV-Visible spectrophotometer [122].

(f) In vitro Release Kinetics

Franz diffusion apparatus is employed to determine drug permeability in microemulsion through cell membrane. Franz diffusion cell consists of cell where premeasured slaughtered animal skin like pig ear or bovine skin is pre-hydrated in distilled water at 25°C for 24 hours. The receptor compartment shall be filled with 6.8 pH phosphate buffer and the donor compartment shall be charged with 10 mg of pure drug or 5 mL of the microemulsions. The diffusion medium is stirred constant for 100 rpm throughout the process using a suitable magnetic stirrer. At specific time interval of 1 hour, about 2 ml samples are withdrawn from the receptor compartment continued for 8-10 hour and intermediate replaced with equal volume of fresh buffer. These samples will be diluted with diffusion medium and the absorbance can be measured spectrophotometrically at particular wavelength or chromatographically obtained area is compared to that of standard one [125] thus penetration and efficacy of formulated microemulsion shall be characterised.

CONCLUSION

To date therapeutic protein, enzyme and peptide form of microemulsions have been shown their efficiency in protection of labile drug, control drug release phenomena, enhancement of drug solubility, extending bioavailability, reduction patient variability and so on. Incorporation of particular protein in microemulsion by considering ability to get deliver within the body by appropriate choosing of phases and techniques in therapeutics of acute and chronic disorders including cancer, infections and viral or autoimmune pathologies is paramount importance. This paper summarises not only the different phases but also the variant methods employed in order to formulate microemulsion with consideration of maximum therapeutic efficacy. Furthermore, it has been proved that formulated preparations are suitable one in specific routes of administration of drugs. As far as compatibility studies, varieties of techniques are available for determination of compatibility of protein drugs with excipients but there applications are limited due to denaturing property of proteins and peptides. However with implementation of these techniques in determination of compatibility and characterisation methods the effort could be made in transformation of these ‘macro’ molecules into the substantial ‘micro’ emulsion drug delivery vehicles.

ACKNOWLEDGEMENT

The authors highly appreciate University Grants Commission, New Delhi for UGC-BSR fellowship for their funding and support during the tenure.

REFERENCES

13. Mark R Prausnitz, Skin barrier and transdermal drug delivery, Medical Therapy Section. 19, 2065-2073.
25